Motesanib, a drug meant for those cancers which are difficult to treat , has unfortunately not lived up to expectations in the phase III trial. Infact, it did not make any significant contribution in improving the survival rate among victims of non-small cell lung cancer (NSCLC).
Nearly 1,090 patients with advanced nonsquamous NSCLC were part of the study.
Source-Medindia